Xilio Therapeutics Unveils Promising Phase 1 Data for Tumor-Activated IL-12 in Advanced Solid Tumors
Reuters
Nov 07
<a href="https://laohu8.com/S/XLO">Xilio Therapeutics</a> Unveils Promising Phase 1 Data for Tumor-Activated IL-12 in Advanced Solid Tumors
Xilio Therapeutics, Inc. has announced new data from its pipeline of tumor-activated immuno-oncology therapies at the Society for Immunotherapy of Cancer $(SITC)$ 40th Annual Meeting, held from November 5-9, 2025. The company presented preclinical data on its masked T cell engager platform, as well as clinical data from its ongoing studies. Phase 1 data for efarindodekin alfa, a tumor-activated IL-12, and Phase 2 data related to circulating tumor DNA (ctDNA) for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, were showcased during the event. Xilio also announced development milestones for its masked T cell engager programs, with plans to advance at least two candidates into IND-enabling studies and submit IND applications in 2027. Copies of the presentations are available on the Xilio Therapeutics website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9571048-en) on November 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.